Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma

Dong M. Shin, Bonnie S. Glisson, Fadlo R. Khuri, Lawrence Ginsberg, Vali Papadimitrakopoulou, J. Jack Lee, Kristie Lawhorn, Ann M. Gillenwater, Kie Kian Ang, Gary L. Clayman, David Callender, Waun Ki Hong, Scott M. Lippman

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Purpose: To assess the activity and toxicity profile of combined taxol (paclitaxel), ifosfamide, and platinum (cisplatin) (TIP) in patients with recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck. Patients and Methods: Recurrent or metastatic head and neck SCC patients received paclitaxel 175 mg/m2 in a 3-hour infusion on day 1; ifosfamide 1,000 mg/m2 in a 2-hour infusion on days 1 through 3; mesna 600 mg/m2 on days 1 through 3; and cisplatin 60 mg/m2 on day 1, repeated every 3 to 4 weeks. All were premedicated with dexamethasone, diphenhydramine, and cimetidine. Prophylactic hematopoietic growth factors were not permitted. Results: Fifty-two patients were assessable for response and toxicity; 53 for survival (local-regional recurrence alone in 57% and distant metastasis with or without local-regional recurrence in 43%). Overall response rate was 58% (30 of 52) of patients; complete response rate was 17% (nine of 52) of patients, with six complete responses that continued for a median 15.7 + months. Median follow-up of all patients was 17.7 months. Median survival was 8.8 months (95% confidence interval [CI] 8.1 to 17.5 months). Toxicity was relatively well tolerated and caused no deaths. The most frequent moderate- to-severe toxicity (90% of patients) was transient grades 3 to 4 neutropenia; neutropenic fever occurred in 27%. Grade 3 peripheral neuropathy occurred in three patients, none had grade 4. Grade 3 mucositis occurred in only one patient, none had grade 4. Conclusion: TIP had major activity in this setting, with a 58% objective response rate, 17% complete response rate, durable complete response (six of nine persisting), and relatively well- tolerated toxicity, with no toxic deaths. The activity of TIP, a novel taxol- cisplatin-based regimen, in recurrent or metastatic head and neck SCC should be confirmed in a phase III trial.

Original languageEnglish
Pages (from-to)1325-1330
Number of pages6
JournalJournal of Clinical Oncology
Volume16
Issue number4
StatePublished - Apr 1998
Externally publishedYes

Fingerprint

Ifosfamide
Paclitaxel
Platinum
Carcinoma, squamous cell of head and neck
Mesna
Diphenhydramine
Recurrence
Mucositis
Survival
Poisons
Cimetidine
Peripheral Nervous System Diseases
Neutropenia
Dexamethasone
Intercellular Signaling Peptides and Proteins
Fever
Confidence Intervals
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shin, D. M., Glisson, B. S., Khuri, F. R., Ginsberg, L., Papadimitrakopoulou, V., Lee, J. J., ... Lippman, S. M. (1998). Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. Journal of Clinical Oncology, 16(4), 1325-1330.

Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. / Shin, Dong M.; Glisson, Bonnie S.; Khuri, Fadlo R.; Ginsberg, Lawrence; Papadimitrakopoulou, Vali; Lee, J. Jack; Lawhorn, Kristie; Gillenwater, Ann M.; Ang, Kie Kian; Clayman, Gary L.; Callender, David; Hong, Waun Ki; Lippman, Scott M.

In: Journal of Clinical Oncology, Vol. 16, No. 4, 04.1998, p. 1325-1330.

Research output: Contribution to journalArticle

Shin, DM, Glisson, BS, Khuri, FR, Ginsberg, L, Papadimitrakopoulou, V, Lee, JJ, Lawhorn, K, Gillenwater, AM, Ang, KK, Clayman, GL, Callender, D, Hong, WK & Lippman, SM 1998, 'Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma', Journal of Clinical Oncology, vol. 16, no. 4, pp. 1325-1330.
Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. Journal of Clinical Oncology. 1998 Apr;16(4):1325-1330.
Shin, Dong M. ; Glisson, Bonnie S. ; Khuri, Fadlo R. ; Ginsberg, Lawrence ; Papadimitrakopoulou, Vali ; Lee, J. Jack ; Lawhorn, Kristie ; Gillenwater, Ann M. ; Ang, Kie Kian ; Clayman, Gary L. ; Callender, David ; Hong, Waun Ki ; Lippman, Scott M. / Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 4. pp. 1325-1330.
@article{d0799556a6aa43ccadb22bd74720e7b1,
title = "Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma",
abstract = "Purpose: To assess the activity and toxicity profile of combined taxol (paclitaxel), ifosfamide, and platinum (cisplatin) (TIP) in patients with recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck. Patients and Methods: Recurrent or metastatic head and neck SCC patients received paclitaxel 175 mg/m2 in a 3-hour infusion on day 1; ifosfamide 1,000 mg/m2 in a 2-hour infusion on days 1 through 3; mesna 600 mg/m2 on days 1 through 3; and cisplatin 60 mg/m2 on day 1, repeated every 3 to 4 weeks. All were premedicated with dexamethasone, diphenhydramine, and cimetidine. Prophylactic hematopoietic growth factors were not permitted. Results: Fifty-two patients were assessable for response and toxicity; 53 for survival (local-regional recurrence alone in 57{\%} and distant metastasis with or without local-regional recurrence in 43{\%}). Overall response rate was 58{\%} (30 of 52) of patients; complete response rate was 17{\%} (nine of 52) of patients, with six complete responses that continued for a median 15.7 + months. Median follow-up of all patients was 17.7 months. Median survival was 8.8 months (95{\%} confidence interval [CI] 8.1 to 17.5 months). Toxicity was relatively well tolerated and caused no deaths. The most frequent moderate- to-severe toxicity (90{\%} of patients) was transient grades 3 to 4 neutropenia; neutropenic fever occurred in 27{\%}. Grade 3 peripheral neuropathy occurred in three patients, none had grade 4. Grade 3 mucositis occurred in only one patient, none had grade 4. Conclusion: TIP had major activity in this setting, with a 58{\%} objective response rate, 17{\%} complete response rate, durable complete response (six of nine persisting), and relatively well- tolerated toxicity, with no toxic deaths. The activity of TIP, a novel taxol- cisplatin-based regimen, in recurrent or metastatic head and neck SCC should be confirmed in a phase III trial.",
author = "Shin, {Dong M.} and Glisson, {Bonnie S.} and Khuri, {Fadlo R.} and Lawrence Ginsberg and Vali Papadimitrakopoulou and Lee, {J. Jack} and Kristie Lawhorn and Gillenwater, {Ann M.} and Ang, {Kie Kian} and Clayman, {Gary L.} and David Callender and Hong, {Waun Ki} and Lippman, {Scott M.}",
year = "1998",
month = "4",
language = "English",
volume = "16",
pages = "1325--1330",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma

AU - Shin, Dong M.

AU - Glisson, Bonnie S.

AU - Khuri, Fadlo R.

AU - Ginsberg, Lawrence

AU - Papadimitrakopoulou, Vali

AU - Lee, J. Jack

AU - Lawhorn, Kristie

AU - Gillenwater, Ann M.

AU - Ang, Kie Kian

AU - Clayman, Gary L.

AU - Callender, David

AU - Hong, Waun Ki

AU - Lippman, Scott M.

PY - 1998/4

Y1 - 1998/4

N2 - Purpose: To assess the activity and toxicity profile of combined taxol (paclitaxel), ifosfamide, and platinum (cisplatin) (TIP) in patients with recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck. Patients and Methods: Recurrent or metastatic head and neck SCC patients received paclitaxel 175 mg/m2 in a 3-hour infusion on day 1; ifosfamide 1,000 mg/m2 in a 2-hour infusion on days 1 through 3; mesna 600 mg/m2 on days 1 through 3; and cisplatin 60 mg/m2 on day 1, repeated every 3 to 4 weeks. All were premedicated with dexamethasone, diphenhydramine, and cimetidine. Prophylactic hematopoietic growth factors were not permitted. Results: Fifty-two patients were assessable for response and toxicity; 53 for survival (local-regional recurrence alone in 57% and distant metastasis with or without local-regional recurrence in 43%). Overall response rate was 58% (30 of 52) of patients; complete response rate was 17% (nine of 52) of patients, with six complete responses that continued for a median 15.7 + months. Median follow-up of all patients was 17.7 months. Median survival was 8.8 months (95% confidence interval [CI] 8.1 to 17.5 months). Toxicity was relatively well tolerated and caused no deaths. The most frequent moderate- to-severe toxicity (90% of patients) was transient grades 3 to 4 neutropenia; neutropenic fever occurred in 27%. Grade 3 peripheral neuropathy occurred in three patients, none had grade 4. Grade 3 mucositis occurred in only one patient, none had grade 4. Conclusion: TIP had major activity in this setting, with a 58% objective response rate, 17% complete response rate, durable complete response (six of nine persisting), and relatively well- tolerated toxicity, with no toxic deaths. The activity of TIP, a novel taxol- cisplatin-based regimen, in recurrent or metastatic head and neck SCC should be confirmed in a phase III trial.

AB - Purpose: To assess the activity and toxicity profile of combined taxol (paclitaxel), ifosfamide, and platinum (cisplatin) (TIP) in patients with recurrent or metastatic squamous cell carcinoma (SCC) of the head and neck. Patients and Methods: Recurrent or metastatic head and neck SCC patients received paclitaxel 175 mg/m2 in a 3-hour infusion on day 1; ifosfamide 1,000 mg/m2 in a 2-hour infusion on days 1 through 3; mesna 600 mg/m2 on days 1 through 3; and cisplatin 60 mg/m2 on day 1, repeated every 3 to 4 weeks. All were premedicated with dexamethasone, diphenhydramine, and cimetidine. Prophylactic hematopoietic growth factors were not permitted. Results: Fifty-two patients were assessable for response and toxicity; 53 for survival (local-regional recurrence alone in 57% and distant metastasis with or without local-regional recurrence in 43%). Overall response rate was 58% (30 of 52) of patients; complete response rate was 17% (nine of 52) of patients, with six complete responses that continued for a median 15.7 + months. Median follow-up of all patients was 17.7 months. Median survival was 8.8 months (95% confidence interval [CI] 8.1 to 17.5 months). Toxicity was relatively well tolerated and caused no deaths. The most frequent moderate- to-severe toxicity (90% of patients) was transient grades 3 to 4 neutropenia; neutropenic fever occurred in 27%. Grade 3 peripheral neuropathy occurred in three patients, none had grade 4. Grade 3 mucositis occurred in only one patient, none had grade 4. Conclusion: TIP had major activity in this setting, with a 58% objective response rate, 17% complete response rate, durable complete response (six of nine persisting), and relatively well- tolerated toxicity, with no toxic deaths. The activity of TIP, a novel taxol- cisplatin-based regimen, in recurrent or metastatic head and neck SCC should be confirmed in a phase III trial.

UR - http://www.scopus.com/inward/record.url?scp=0031897977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031897977&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 1325

EP - 1330

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -